Sociodemographic and clinical characteristics of HIV-infected individuals
| Characteristic . | Rapid progressors (n = 13) . | Normal progressors (n = 17) . | Viremic slow progressors (n = 7) . | Aviremic slow progressors (n = 6) . | P . |
|---|---|---|---|---|---|
| Age at first visit, y | 33 ± 7 | 39 ± 7 | 43 ± 4 | 41 ± 8 | .02* |
| Sex (male/female) | 12/1 | 17/0 | 7/0 | 3/3 | NS |
| Race (white/other) | 12/1 | 16/1 | 6/1 | 5/1 | NS |
| Route of transmission | 8 MSM, 3 HS, 2 IDU | 16 MSM, 1 IDU | 6 MSM, 1 IDU | 3 MSM, 3 HS | NS |
| CD4+ T cells/mm3 | |||||
| Acute phase | 544 ± 143 | 797 ± 210 | na | na | .002 |
| Early phase | 428 ± 148 | 685 ± 185 | na | na | .001 |
| Chronic phase | 394 ± 231 | 601 ± 271 | 532 ± 130 | 887 ± 122 | NS |
| Nadir | 254 ± 118 | 432 ± 140 | 506 ± 129 | 506 ± 175 | .0005† |
| Viremia, ×103 copies/mL | |||||
| Acute phase | 369 ± 703 | 85.6 ± 132 | na | na | NS |
| Early phase | 127 ± 184 | 80.1 ± 100 | na | na | NS |
| Chronic phase | 8.3 ± 17 | 101 ± 225 | 3.3 ± 1.5 | < 0.005‡ | .0009§ |
| Peak | 570 ± 808 | 202 ± 236 | 8.5 ± 6.5 | 0.065 ± 0.027 | < .0001‖ |
| Characteristic . | Rapid progressors (n = 13) . | Normal progressors (n = 17) . | Viremic slow progressors (n = 7) . | Aviremic slow progressors (n = 6) . | P . |
|---|---|---|---|---|---|
| Age at first visit, y | 33 ± 7 | 39 ± 7 | 43 ± 4 | 41 ± 8 | .02* |
| Sex (male/female) | 12/1 | 17/0 | 7/0 | 3/3 | NS |
| Race (white/other) | 12/1 | 16/1 | 6/1 | 5/1 | NS |
| Route of transmission | 8 MSM, 3 HS, 2 IDU | 16 MSM, 1 IDU | 6 MSM, 1 IDU | 3 MSM, 3 HS | NS |
| CD4+ T cells/mm3 | |||||
| Acute phase | 544 ± 143 | 797 ± 210 | na | na | .002 |
| Early phase | 428 ± 148 | 685 ± 185 | na | na | .001 |
| Chronic phase | 394 ± 231 | 601 ± 271 | 532 ± 130 | 887 ± 122 | NS |
| Nadir | 254 ± 118 | 432 ± 140 | 506 ± 129 | 506 ± 175 | .0005† |
| Viremia, ×103 copies/mL | |||||
| Acute phase | 369 ± 703 | 85.6 ± 132 | na | na | NS |
| Early phase | 127 ± 184 | 80.1 ± 100 | na | na | NS |
| Chronic phase | 8.3 ± 17 | 101 ± 225 | 3.3 ± 1.5 | < 0.005‡ | .0009§ |
| Peak | 570 ± 808 | 202 ± 236 | 8.5 ± 6.5 | 0.065 ± 0.027 | < .0001‖ |
Age, CD4, and viremia are expressed as mean ± SD. Sex, race, and route of transmission were compared using χ2 test. Pairwise comparisons of CD4 for acute and early phases were performed using unpaired t tests. Pairwise comparisons of viremia for acute and early phases were performed using Mann-Whitney tests. Comparisons among all groups (age at first visit, CD4, and viremia in the chronic phase and nadir CD4) were performed with the one-way analysis of variance test. HS, heterosexuals; IDU, intravenous drug users; MSM, men who have sex with men; NS, not significant; and na, not available.
P = .04 and .003 for the comparisons of age between rapid and normal progressors and rapid progressors and viremic slow progressors, respectively, as determined by the Mann-Whitney test.
P = .0008 and .001 and .02 nadir CD4 for the comparison between rapid and normal progressors, rapid and viremic slow progressors, and rapid and aviremic slow progressors, respectively, as determined by the Mann-Whitney test.
Fifty copies/mL corresponds to the detection threshold of the viral load test.
P = .04, .02, .002, and .002 for the comparison of viremia in chronic phase between rapid and normal progressors, normal progressors and viremic slow progressors, normal progressors and aviremic slow progressors, and viremic and aviremic slow progressors, respectively, as determined by the Mann-Whitney test.
P = .006, .0007, .0005, .0004, and .001 for the comparison of peak viremia between rapid progressors and viremic slow progressors, rapid progressors and aviremic slow progressors, normal progressors and viremic slow progressors, normal progressors and aviremic slow progressors, and viremic and aviremic slow progressors, respectively, as determined by the Mann-Whitney test.